-+ 0.00%
-+ 0.00%
-+ 0.00%

AURIGENE ONCOLOGY LIMITED ANNOUNCES ENCOURAGING INITIAL DATA FROM 1ST TWO COHORTS OF PHASE 1 STUDY OF AUR112, AN ORAL SMALL MOLECULE INHIBITOR OF MALT1, IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

Reuters·12/02/2025 13:00:01

Please log in to view news